What is the role of stem cell transplantation (SCT) in the treatment of Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL) with partial remission?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Patients in first partial remission should be considered for high-dose chemotherapy plus autologous SCT. The outcome of treatment in these patients with conventional chemotherapy regimens is usually poor. In a report by Philip and Biron, the results of bone marrow transplantation in patients with Burkitt lymphoma (BL) in partial remission was a 70% survival rate at 2 years. [65]

Subsequent randomized studies in aggressive non-Hodgkin lymphoma (NHL) have failed to clearly show an advantage for high-dose chemotherapy plus autologous SCT. Currently, patients with Burkitt lymphoma (BL) whose disease demonstrates chemosensitivity and who achieve a good partial remission after front-line therapy should be considered for high-dose chemotherapy plus autologous SCT. [27]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!